Germany

LYOCONTRACT has partnered with Syntegon, a leading equipment supplier, to install a complete filling and lyophilization line at the new facility.

The company showcased three new angiography platforms—Artis genio, Artis icono.explore, and Artis icono.vision—which harness artificial intelligence to enhance the precision of liver cancer embolization treatments.

The platform integrates visual inspection capabilities with advanced leak detection technology, processing up to 600 vials per minute while maintaining rigorous quality standards.

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.

The ACCESS-AD project launches in January 2026 with an ambitious goal to establish a collaborative, patient-centered approach to Alzheimer’s care throughout Europe.

Optiq AI is integrated across three new imaging platforms: Artis genio, Artis icono.explore, and Artis icono.vision/Artis pheno.vision.

Mjn-neuro’s wearable sensor uses artificial intelligence (AI) to analyze electrical brain signals and predict when a seizure will occur.

Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.

The company’s Pharma business unit led the strong performance, delivering sales growth of 32%, including 20% organic growth.